Basal | 4 week | 8 week | 12 week | 16 week | |
---|---|---|---|---|---|
EASI score (scale 0–72) | 29 | 12.5 | 4.6 | 4 | 4 |
SCORAD-total score (scale 0–103) | 78 | 40.9 | 45.5 | 20 | 16 |
IGA score (scale 0–4) | 4 | 3 | 3 | 2 | 2 |
NRS pruritus score (scale 0–10) | 8 | 3 | 8 | 2 | 1 |
NRS sleep score (scale 0–10) | 9 | 1 | 8 | 1 | 1 |
POEM score (scale 0–30) | 21 | 2 | 20 | 2 | 2 |
DLQI score (scale 0–28) | 13 | 15 | 7 | 1 | 1 |
FEV1 (L) | 2.60 | 2.48 | 2.5 | 2.5 | 2.72 |
FEV1 (% predicted) | 89.4% | 84% | 85% | 85% | 93.3% |
ACT score (scale 0–25) | 21 | 24 | 25 | 25 | 25 |
ACQ-5 score (scale 0–6) | 0.9 | 0.7 | 0.1 | 0.0 | 0.0 |
AQLQ score (scale 0–7) | 6.3 | 6.6 | 6.8 | 6.7 | 6.7 |
Bilateral ENPS (scale 0–8) | 3 | – | – | – | 0 |
SNOT-22 score (scale 0–110) | 20 | 14 | 12 | 15 | 11 |
Loss of smell score (scale 0–3) | 2 | 2 | 1 | 1 | 1 |
Rhinitis disease severity (visual analog scale 0–10 cm) | 6 | 5 | 3 | 3 | 2 |
RQLQ (scale 0–6) | 2.85 | 2.64 | 2.51 | 2.64 | 2.31 |
Total IgE levels, KUA/L | 1633 kUA/L | – | – | – | 901.8 kUA/L |
Blood eosinophil Count, cells/μ | 239/mm3 | – | – | – | 50/mm3 |
Concomitant medications | Clobetasol proprionate oinment 0.05%, 2 times a day; Desloratadine 5 mg/die; Beclomethasone/formoterol fumarate (200/6 μg)two inhalations twice daily | Desloratadine 5 mg as needed; Beclomethasone/formoterol fumarate (200/6 μg) one inhalation twice daily | Desloratadine 5 mg as needed; Beclomethasone/formoterol fumarate (100/6 μg) one inhalation twice daily | Beclomethasone/formoterol fumarate (100/6 μg) one inhalation twice daily | Beclomethasone/formoterol fumarate (100/6 μg) one inhalation as needed |